Almonertinib and Lastet for EGFR-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, Almonertinib and Lastet, for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) that cannot be removed by surgery or cured with radiation and chemotherapy. The goal is to see if the combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lung cancer must be a type called non-small cell lung cancer (NSCLC) that has spread or come back, and cannot be treated with surgery or curative radiation/chemotherapy.
- Your tumor must have an EGFR mutation (a specific change in the cancer cells).
- You must be able to provide a sample of your tumor (either from a previous surgery or a new biopsy) for testing.
- You must have at least one tumor that can be measured on a scan.
- You must be in good enough health to have a life expectancy of at least 3 months and a performance status of 0 or 1 (able to carry on daily activities).
- Your blood counts, liver, and kidney function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two targeted drugs (andamertinib and anlotinib) for lung cancer that has EGFR mutations and has progressed after a prior EGFR TKI. It aims to see if the combination can shrink tumors and help control the cancer.
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Hear when a new Lung Cancer Non-small Cell Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.